Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Neuroendocrine Tumors 4Carcinoid Tumor 3Pheochromocytoma 1Paraganglioma 1Neoplasm Metastasis 1Gastrointestinal Neoplasms 1Carcinoma, Merkel Cell 1

Interventions

Oxaliplatin 10Capecitabine 9Cisplatin 8Fluorouracil 5Leucovorin 4Bevacizumab 4tegafur-gimeracil-oteracil 3pemigatinib 3atezolizumab 3Nivolumab 3trebananib 2ponatinib 2pembrolizumab 2avelumab 2apatinib 2alectinib 2XELOX 2Standard of Care 2S 1 (combination) 2Radiotherapy 2Radiosurgery 2Ocoxin 2Irinotecan 2Ipilimumab 2Gemcitabine 2Folfox protocol 2Everolimus 2Erlotinib Hydrochloride 2Acupuncture Therapy 2zanidatamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Gastrointestinal Neoplasms × lanreotide × Clear all
NCT02859064 2023-12-05

Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres

SCRI Development Innovations, LLC

Phase 2 Terminated
6 enrolled 12 charts
EndocrineGastrointestinalNET

Carcinoid Tumor, Gastrointestinal Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡